Biochemical failure after definitive therapy of prostate cancer: Defining the chicken switch

International Journal of Radiation Oncology Biology Physics

Volumn 55, Issue 4, 2003, Pages 859-860

  Johnstone, Peter A S ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; BIOCHEMISTRY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COST OF ILLNESS; DISEASE MARKER; EDITORIAL; EMOTION; FOLLOW UP; HEALTH STATUS; HUMAN; LIFE EXPECTANCY; MEDICAL SOCIETY; METASTASIS; MULTIMODALITY CANCER THERAPY; ONCOLOGY; PATIENT CARE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; UROLOGY;

EID: 0037443504     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)04214-1     Document Type: Editorial

References (15)

1. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol. 163:2000;1632-1642.
2. Leventis A.K., Shariat S.F., Kattan M.V., Butler E.B., Wheeler T.M., Slawin K.M. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 19:2001;1030-1039.
3. Garg MK, Tekyi-Mensah S, Bolton S; et al. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 1998;51:998-1002.
4. Do T., Parker R.G., Do C., Tran L., Do L., Dolkar D. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J Sci Am. 4:1998;324-330.
5. Amling C.L., Lerner S.E., Martin S.K., Slezak J.M., Blute M.L., Zincke H. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol. 161:1999;857-862.
6. Johnstone P.A.S., Booth R., Riffenburgh R.H., Amling C.L., Kane C.J., Moul J.W. Initiation of salvage therapy for prostate cancer. Prostate Cancer Prost Dis. 5:2002;136-143.
7. Duchesne GM, Millar JL, Moraga V, Rosenthal M, Royce P, Snow R. What to do for prostate cancer patients with a rising PSA? - A survey of Australian practice. Int J Radiat Oncol Biol Phys (current issue data).
8. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. JAMA. 341:1999;1781-1788.
9. Murphy G.P. Review of phase II hormone refractory prostate cancer trials. Urology. 54:(Suppl. 6A):1999;19-21.
10. Byar D.P. studies of cancer of the prostate. Cancer. 32:1973;1126-1130.
11. Immediate versus deferred treatment for advanced prostatic cancer; initial results of the Medical Research Council trial. Br J Urol. 79:1997;235-246.
12. Tangen C, Crawford ED, Faulkner J, Thompson I, Eisenberger M, Hussain M. Ten-year survival in patients with metastatic (M+) prostate cancer (CaP): Analysis of Southwest Oncology Group. (SWOG) 8894. Proc ASCO 2002;188a(#749).
13. Moul JW, McLeod DG, Amling C; et al. Assessment of biochemical disease free survival (DFS) in patients with hormonal therapy (HT) started for PSA-only recurrence following radical prostatectomy. J Urol 2002;167:174S (#699).
14. Walsh P.C., DeWeese T.L., Eisenberger M.A. A structured debate Immediate versus deferred androgen suppression in prostate cancer - Evidence for deferred treatment. J Urol. 166:2001;508-516.
15. Parker C.C., Dearnaley D.P. The management of PSA failure after radical radiotherapy for localized prostate cancer. Radiother Oncol. 49:1998;103-110.